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Abstract
According to recent statistics, 96 million apparent dengue infections were estimated worldwide in 2010. This figure
is by far greater than the WHO prediction which indicates the rapid spread of this disease posing a growing threat
to the economy and a major challenge to clinicians and health care services across the globe particularly in the
affected areas.
This article aims at bringing to light the current epidemiological and clinical status of the dengue fever. The
relationship between genetic mutations, single nucleotide polymorphism (SNP) and the pathophysiology of disease
progression will be put into perspective. It will also highlight the recent advances in dengue vaccine development.
Thus far, a significant progress has been made in unraveling the risk factors and understanding the molecular
pathogenesis associated with the disease. However, further insights in molecular features of the disease and the
development of animal models will enormously help improving the therapeutic interventions and potentially
contribute to finding new preventive measures for population at risk.
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Background
Dengue fever is a major cause of illness and death
worldwide. The disease is caused by dengue virus which
gets transmitted to humans by the bites of infected
mosquitoes, Aedes (Ae.) aegypti and Ae. albopictus [1].
The disease represents a global health issue as it is en-
demic in around 100 countries, most of which are in
tropical and sub-tropical areas. Over the last decades,
the incidence rate and the geographic distribution of
dengue have rapidly increased (almost 30-fold). Data
from the World Health Organization (WHO) estimates
up to 100 million cases of dengue fever each year [2].
However, a recent published work by Bhatt et al. (2013)
suggested that the burden of dengue is far more than
the WHO estimation and indicated that 390 million in-
fections of dengue virus could have happened every year
[3]. Changes in dengue epidemiology and the increase in
incidence rates (with and without co-morbidities) have
led the WHO to propose a new dengue classification
system according to disease severity (Fig. 1) [2].
Etiology and mode of transmission
Dengue fever is caused by infection with dengue virus
(DENV). The DENV is a vector-borne virus transmitted
to humans primarily by bites from two mosquito species,
Ae. aegypti or Ae. albopictus. DENV is a single positive-
stranded RNA virus belonging to Flavivirus genus of the
Flaviviridae family and has 4 major serotypes (DENV
1–4) that are antigenically distinct from each other. Each
DENV serotype is phylogenetically distinct suggesting
that each serotype could be considered a separate virus
[4]. Three dengue serotypes out of four (DENV 1–3)
have been found in Middle Eastern countries including
Saudi Arabia and Yemen. Interestingly, DENV-1 strain
isolated in Saudi Arabia exhibited a high genetic similarity
with DENV-1 strain isolated from Asian population, sug-
gesting a widespread of the Asian genotype, probably
through Asian pilgrims [5, 6]. A recently published art-
icle has unveiled a new serotype (DENV-5), to be
added to the existing ones [7]. This discovery is still
controversial and little-known enough to conclude
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how the 5th dengue serotype might add to the burden
associated with dengue infection.
Mosquitoes transmit the virus by feeding on blood
of infected persons. At first, the virus infects and
replicates in the mid-gut epithelium of the mosquito
and then spreads to other organs until it reaches the
salivary glands after 10–14 days where it can be in-
oculated to another person during subsequent blood
meal. Vertical transmission of DENV in mosquitoes,
i.e. from mosquito to larvae has been reported by a
number of research groups. In India, Angel & Joshi
(2008) reported the detection of dengue virus by in-
direct fluorescence antibody test (IFAT) in laboratory
reared mosquitoes originating from larvae collected
from urban and rural areas [8]. A similar study was
conducted in Brazil by Martins et al. (2012) and con-
firmed the isolation of DENV-type 3 in Ae. albopictus
larvae and DENV-type 2 in Ae. aegypti larvae [9]. Simi-
lar findings were also reported in Mexico [10] and
Indonesia [11]. On the other hand, mother-to-infant
transmission of dengue virus via cord blood or breast
milk remains controversial [12–14].
Clinical manifestations
Based on the results from several studies, the WHO has
launched a new dengue classification. This classification
divides dengue cases into a) cases with/without warning
signs and b) severe dengue cases [2]. However, it is import-
ant to note that numerous research groups have debated
the rational of this classification as it does not fit their
unique local settings. The criteria for dengue case classifica-
tion are presented in Fig. 1.
Clinically, dengue infection has a broad spectrum of
features. The vast majority of cases are asymptomatic
and passes unnoticed. Typically, the symptoms start to
be prominent after an incubation period of 3–10 days
[15]. The severity of the clinical manifestations varies
from mild symptoms to severe life threatening symp-
toms in the case of dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS) [16]. Predicting the
progression of the mild signs to a severe DHF/DSS re-
mains a challenge due to non-specificity of clinical
presentation and the incomplete understanding of
pathophysiology of the disease and its underlying mo-
lecular mechanisms.
Dengue with warning signs
The early signs of the disease are non-specific. According
to the WHO classification (2009), DF is characterized by
febrile episode (≥40 °C for 2–7 days) frequently associated
with rash, nausea, vomiting, and headache. Although the
disease affects people of all ages from infancy through to
adulthood [17], epidemiological data showed that children
tend to tolerate this phase of illness better than adults
[18]. The persistence of the aforementioned symptoms
and appearance of other symptoms, such as abdominal
pain, mucosal bleed, and lethargy and restlessness can be
seen 3–7 days later. Laboratory analysis of mild dengue
fever cases usually shows abnormal leukocyte counts and
moderate elevation of the hepatic amino-transferase
Fig. 1 WHO dengue case classification (Adopted from; Dengue Guidelines for diagnosis, treatment, prevention and control, New edn. Geneva:
WHO; 2009)
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enzyme activity [19]. The emergence of these symptoms is
a warning sign for disease progression to severe form
(DHF/DSS) if therapeutic intervention is not under-
taken. At this stage clinical intervention and continuous
surveillance are imperative to prevent vascular leakage,
especially in an endemic area.
Severe dengue
This form of dengue infection can be attributed to any
of the four known serotypes DENV 1–4. The likelihood
of developing DHF/DSS is high in patients who have ex-
perienced dengue infection in the past with heterogeneous
serotype [20]. About 5–10 % of patients progress to
develop a severe DHF/DSS which can be fatal unless
treated promptly [21]. This form develops at a late stage
of DF, where patients may go through defervescence phase
characterized by a sudden drop of body’s temperature. This
phase is also distinguished by severe bleeding, particularly
bleeding from the gastrointestinal tract (black, tarry stool),
and thrombocytopenia (<50,000/mm3), which may affect
up to 50 % of DHF cases [22]. Interestingly, there was an
observed negative correlation between the severity of DHF
and the level of platelets in the blood. The exact mechan-
ism of this correlation has yet to be delineated. The drop
of platelet counts and the loss of their functionality
lead to a vascular fragility increasing the risk of
hemorrhage and plasma leakage [23]. It has been sug-
gested that during acute phase of the infection DENV
replicates quickly in platelets, as this is very critical
for virus survival and dissemination [24, 25].
The existence of other symptoms such as retro-orbital
pain, maculopapular rash, petechiae, or bleeding from
the nose or gums will help making definitive diagnosis
for DF [25]. Evidence of plasma leakage in various body
cavities such as the pleural cavity and the peritoneal
cavity, associated with profuse perspiration, adynamia,
and sometimes fainting are signs of rapid progression to
shock. Subsidence in systolic pressure and hypotension
may result in profound shock, known as dengue shock
syndrome (DSS). The duration of DSS for a long time
might predispose to further complications such as massive
bleeding, disseminated intravascular coagulopathy (DIC),
respiratory failure, multi-organ failure, and infrequently
encephalopathy leading to death [26, 27]. It has been
proposed that case fatality related to DHF may reach
15 % of all cases, however, proper medical care and
symptomatic management can reduce mortality rate
to less than 1 % [28].
Diagnosis
An early and accurate laboratory diagnosis of dengue
infection is of paramount importance in the manage-
ment of the disease. It has been estimated that the
number of misdiagnosed dengue cases could reach a
record ratio of 50 % of all cases, mainly due to a large
disparity of dengue signs and symptoms which overlap
with the symptoms of other viral infections, especially
for persons living in or traveling to endemic areas of
tropical infectious diseases. Dengue fever should be
distinguished from other illnesses which share similar
symptoms such as chikungunya, Mayaro fever, Ross
River fever, West Nile fever, Zika fever, yellow fever
and viral hemorrhagic fevers [4]. Until the antiviral
vaccine becomes available, the prevention of severe
cases and cut-down of the economic burden of the
disease rely enormously on early and accurate diagno-
sis. The latter is made possible through the availability
of several diagnostic laboratory and virological tests.
The onset of later stage symptoms of the illness can be
overwhelming and more pathognomonic. Nonetheless,
based on WHO classification schemes, the appearance
of leukopenia in patients with febrile illness is a major
consideration in making diagnosis of dengue infection
[29]. Overall, there is an urgent need to reduce dengue
morbidity and mortality by improving the diagnosis and
molecular analysis of emerging dengue virus. Thus far,
two diagnostic modalities have been applied to detect
the disease at an early stage. The first one is a direct
method targeting the acute phase of dengue disease,
which is based upon detection of genomic RNA by RT-
qPCR or soluble NS1 by antigen capture in blood sam-
ples from viremic patients. The second is the indirect
method that relies on serological tests to detect dengue-
related immunoglobulins par Mac-ELISA for the capture
of specific IgM or indirect ELISA for the capture of anti-
DEN IgGs [30–34].
Genetic alteration/susceptibility to dengue infection
Several risk factors have been associated with dengue in-
fection and its progression to severe DHF/DSS forms.
Recent advances in molecular biology have revealed
that the genetic makeup of the three elements of den-
gue infection (the virus, the vector, and the host) plays
a primordial role in the pathogenesis of the disease and
could potentially contribute to the DHF progression
[19, 24, 35]. Hence, an in-depth analysis of genetic
variability including polymorphism and mutations
could be beneficial in identifying the possible factors
and mechanisms of disease development [36]. The list
of host’s genetic factors that confer susceptibility or re-
sistance to dengue infection is summarized in Table 1.
The mosquito
Like most arboviruses, DENV infect different organs of
the mosquito, including the salivary glands and the central
nervous system. Mosquito infection elicit behavioral
changes including increase of the probing time which lead
to host interruption that might lead to wider spread of the
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virus [37]. It has been demonstrated that DENV infection
induced the expression of cathepsin-B, a putative cystatin,
and a hypothetical ankyrin repeat-containing protein
genes [38]. The latter could alter the efficiency of virus
replication in the salivary gland. This study has shown that
modulation of OBP10 and OBP22 genes expression as well
as DENV infection-responsive odorant-binding protein
genes increase the time length for initiation of probing
before a successful blood meal, resulting in changes in the
host seeking behavior of the mosquito. Comparative ana-
lysis of the salivary gland transcriptomes of native and
DENV-infected Ae. aegypti identified a number of differ-
entially expressed genes related to sugar/protein digestion
enzymes, immunity related genes and blood meal acquisi-
tion enzymes that might have an impact on the efficiency
of viral replication or mosquito feeding behavior. This
study showed that DENV infection alter the expression of
key host-seeking genes in the mosquito’s main olfactory
organs and the antennae [38].
Recent updates have indicated that resistance of Ae.
aegypti to conventional insecticides is related to different
mechanisms, one of which is associated with genetic
abnormalities within the vector’s genome. Single point
mutation in the voltage-gated sodium channel gene at
position 1534 (F1534C) resulting in phenylalanine to
cysteine substitution in Ae. aegypti confers resistance to
permethrin. This mutation is widespread in this vector
in Southeast Asia and Latin America [39, 40]. It has also
been reported that a single amino acid substitution
Valine to Glycine at position 1016 in domain II, segment
6 of the voltage-gated sodium channel gene was associ-
ated with less sensibility of Ae. aegypti to deltamethrin
in Thailand [41].
Human susceptibility to dengue disease
Numerous multi-disciplinary studies confirmed that race,
young age, virus strain, female sex and high body-mass
index correlate well with increased burden of dengue
Table 1 Genetic susceptibility
Gene Function Reference
FcγRIIa Protected from DHF Am. J. Trop. Med. Hyg. 2002, 67(1):
Vitamin D receptor (VDR) Associated with resistance to severe
dengue
Human Immunology. 2012, 73: 1194–1199.
IL-10 Associate with dengue disease
severity
Plos one. 2012, 7 (11), e50387.
TNFa Associate with dengue disease
severity
Plos one. 2012, 7 (11), e50387.
TGFb Associate with dengue disease
severity
Plos one. 2012, 7 (11), e50387.
JAK1 Strongly association with DHF Eur. J. Human Genet. 2010, 18: 1221–1227.
HLA class I alleles A*01, A*0207, A*24, B*07,
B*46, B*51
DHF development Clin Microbio Rev. 2009, 22 (4): 564–581., Tissue Antigens
60:309–318.
HLA class II alleles DQ*1, DR*1, DR*4 DHF development Clin Microbio Rev. 2009, 22 (4): 564–581.
Glucose-6-phosphate dehydrogenase Increase DENV replication Blood Cells Mol. Dis. 2009. 42:267–278.
DC-SIGN Associated with DENV infection Med Sci (Paris). 2005, 21: 905–906.
TAP Prevent DHV/DSS Scand J Immunol 67:618–625
MBL Protect against DENV Hum Immunol 69: 122–128.
CTLA-4 Increases the risk of DHF. Clin Immunol 131: 404–409.
MICB Associated with severe forms of
dengue
Nat Genet. 43(11): 1139–1141
PLCE1 Associated with severe forms of
dengue
Nat Genet. 43(11): 1139–1141
ABO blood group Increases the risk of DHF J Inf Dis 195:1014–1017
HPA2 Enhance susceptibility to DHF Hum Immunol 68:973–979
IFN-γ Enhance severity of dengue disease FEMS Immunol Med Mic 2000; 28: 183–188.
IL-6 Associated with DSS PLoS Negl Trop Dis. 2013, 7(9): e2412.
VCAM-1 Associated with severe dengue Trop Med Health. 2014, 42(4): 137–44.
Oligoadenylate synthetases (OAS) Enhance susceptibility to dengue
infection
Infection, Genetics and Evolution 2013, 14: 390–395.
List of genes that confer susceptibility to dengue infection. The journal volume is given in bold
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infection. The observation that people of African back-
ground are less likely to develop DHF/DSS compared to
their Caucasian counterpart has led to the suggestion that
host genetic variability has a major impact on the clinical
manifestations of dengue infection [42, 43]. Thus, a closer
consideration of human genes regulating the severity of
dengue infection, especially genes associated with the
immune response, might help in controlling disease spread
and improve the acute symptoms of the infection. A num-
ber of studies have investigated the relationship between
the host genetic polymorphisms and DENV infection
(Table 1).
A single nucleotide polymorphism (SNP) in the pro-
moter of CD209/DC-SIGN was associated to increased
risk of developing dengue fever [44]. Association studies
have successfully identified a link between polymor-
phisms in the human major-histocompatibility-complex
(HLA) class I/II genes and non-HLA host genetic factors
and severity of dengue disease [45–47]. Polymorphisms
of the TAP1 and TAP2 genes could be directly associated
with the risk of developing dengue disease among the
primary-infected individuals [48]. Both TAP1 and TAP2
are located within the MHC class II region and homozy-
gosity of the TAP1 at position 1333 and 1637 and for
TAP2 at position 2379, respectively, was found to pro-
tect against developing severe forms of dengue [46].
In an independent study [49], the authors showed that
single nucleotide polymorphism of the oligoadenylate
synthetase genes (OAS1, 2 and 3), of the OAS/RNase L
antiviral immune system, enhance susceptibility to
clinical outcomes of dengue infection. An association
between the severity of the disease and other genes in-
cluding human leukocyte antigen class I and class II
genes, tumor necrosis factor-alpha, FcGRIIA, vitamin D
receptor, transporters associated with antigen presenta-
tion, and JAK1 has also been proposed [50]. The import-
ance of Vit-D in DENV pathogenesis was concluded
from newly-gathered data showing that Vit-D impairs
DENV replication and polymorphism of Vit-D gene in-
creases the expression of both CD209/DC-SIGN and
FcGRIIA receptors that enhance DENV entry in the tar-
get cells [51, 52].
In another study [53], the authors have successfully
applied genome-wide association study (GWAS) ap-
proach to identify loci that confer susceptibility to severe
forms of dengue disease. The investigators used samples
from 2008 children affected with severe dengue infection
against 2018 population control cases in Vietnam. The
data showed that SNPs at two loci, MICB and PLCE1,
significantly increased the likelihood of developing DSS
in children. This finding was further validated in an in-
dependent cohort of 1737 cases and 2934 controls [53].
A SNP in the MICB gene coding for the MHC class I
polypeptide-related sequence B, an inducible activating
ligand for the NKG2D type II receptor of immune cells
could alter the protective role of natural killer and
CD8+ T cells in the host responsiveness to DENV at
the early stage of infection [54, 55]. On the other hand,
PLCE1 plays a primordial role in maintaining intact
vascular endothelial cell barrier function, hence, poly-
morphism of the PLCE1 gene may lead to blood vessels
leakage and circulatory hypovolemia during DSS [56].
Other host candidate genes have also been associated
with early onset dengue disease. Among these genes,
there were receptors/attachment factors for DENV
linked to immune system and inflammatory response.
The chemokines CXCL10, CXCL11 and its respective
chemokine receptor CXCR3 were reported as bio-
markers for severe form of dengue infection [57]. These
results are in agreement with recent emerging data indi-
cating strong association between CXCL10, CXCL11
and CXCR3 and vascular permeability [58]. The three
genes are components of the NF-kB pathway and are in-
volved in the pathogenesis of SARS and West Nile virus
encephalitis [59, 60]. Cerney et al. (2014) interrogated
the effect of DENV on the first point of human contact
which is skin cells. The authors demonstrated an increase
expression of IFN-β, STAT-1 and CCL5 in a susceptible
population of skin dendritic cells (DC) which may facili-
tate the spread of DENV in the blood [61]. This process
depends enormously on vector-derived salivary factors
inoculated on the skin cells [62].
Current status of dengue vaccine development
Till-date, there is no effective, commercially available,
therapy/vaccine for dengue virus. Numerous groups have
already made intensive efforts and made good progress to
develop a safe, affordable and effective vaccine against all
serotypes for global public health [63–69]. Vaccines which
are being developed use various approaches such as live
attenuated viruses, inactivated viruses, subunit vaccines,
DNA vaccines, and chimeric viruses using yellow fever
vaccine and attenuated dengue viruses as backbones
(Table 2).
Live attenuated yellow fever 17D/DENV chimeric vaccine
Currently, only one tetravalent vaccine against dengue
virus, developed by Sanofi-Pasteur (France) has reached
phase III clinical trial and is expected to be launched in
2015. This vaccine is based on the production of four
chimeric live dengue-yellow fever viruses in which the
yellow fever (YF) 17D vaccine sequences encoding the
envelope proteins prM and E genes were substituted by
the prM and E genes from DV of serotype 1, 2, 3, or 4
in a molecular clone of YF-17D [69]. This vaccine was
produced and tested over 6000 people using four dengue
virus isolates from Indonesia and Thailand. This candi-
date vaccine was found to be attenuated and stable in
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animal models with respect to plaque size and yellow fever
virus neurotropism [70]. Results of the clinical trials
showed no adverse effects except moderate injection site
pain, headache, and myalgia. Another randomized, con-
trolled trial was launched using a total of 4002 Thai school
children to investigate the efficacy of a recombinant,
tetravalent vaccine for dengue virus and only 134 dengue
cases were reported [71]. Phase I trial of the vaccine in the
Philippines showed that the seropositivity increased grad-
ually (53, 72 & 92 %) after 1–3 vaccinations against all
four serotypes as compared to control group. The most
promising results were observed in children 2–5 years old
who exhibited high levels of reactivity of 91, 100, 96,
100 % for DENV 1–4; respectively [72].
Another placebo-controlled trial was conducted on
10,275 children from Vietnam (vaccine, n = 6851 Vs
placebo, n = 3424) to determine the clinical efficacy
and safety of CYD-TDV. The results demonstrated
virologically-confirmed cases in 47 % of the vaccine
group as compared to the control group (53 %). The
efficacy was achieved in up to 56.5 % (95 % CI
43.8–66.4). These findings indicated that the vaccine
is highly efficacious with good safety profile when
three injections were given to children with age
group 2–14 years at 0, 6 and 12 months intervals
[73]. The data emerging from another randomized
phase II trial in India indicated that the vaccine has
no serious adverse events and the immunogenicity
and safety of CYD-TDV were satisfactory [74]. A
pilot study carried out in five Latin American countries
where more than 20,000 children aged 9–16 were re-
cruited to receive either the CYD-TDV vaccine or placebo.
The results on efficacy (60.8 %) and safety profiles were
consistent with the previous findings [74, 75]. Interest-
ingly, the vaccine efficacy (80.3 %) against hospitalization
for dengue was promising and represented a step forward
to developing an effective dengue vaccine [75].
Live attenuated DENV delta-30 mutation and intertypic
DENV chimeric vaccines
Other candidate dengue vaccines have been developed
in USA by the Johns Hopkins University and National
Institute of Allergy and Infectious Diseases (NIAID) and
have reached advanced clinical trials [65]. Four live-
attenuated DENV/delta-30 were generated each contain-
ing 30 nucleotides deletion of the 3’-untranslated region
of genomic RNA (delta-30). These vaccines efficiently
impaired viral growth in human liver carcinoma cells
[76]. To improve the attenuation of DENV-2/delta-30
and DENV-3/delta-30, chimeric DENV were developed
by substitution of the prM-E gene region of DENV-4/
delta-30 virus with the prM-E genes of DENV-2 and
DENV-3 [72, 77]. The results from phase I clinical
trial showed that all four live-attenuated DENV/
delta-30 are safe and immunogenic with minor side
effects such as faint rash and transient leucopenia
only after higher dose [78, 79].
Dengue-measles vaccine
Dengue virus serotype-1 antigen was expressed in a vec-
tor based on pediatric live-attenuated Schwarz measles
vaccine (MV) by using the envelope domain III (EDIII)
fused with the ectodomain of the membrane protein
(ectoM). After immunization, long-term production of
DENV-1 serotype-specific neutralizing antibodies was
observed in measles virus susceptible mice [80]. A new
strategy was evaluated based on single minimal tetravalent
DENV antigen expression using viral vector derived from
pediatric live-attenuated measles vaccine (MV). A recom-
binant MV vaccine construct was developed using enve-
lope domain III (EDIII) and ectodomain of the membrane
protein. The neutralizing antibodies were induced against
all four serotypes of dengue virus after two injections in
mice susceptible to MV infection. A strong memory
neutralizing response was observed against all four
Table 2 Current status of dengue vaccine development
No Strategy Developer (s) Current status
1 Live attenuated yellow fever 17D/DENV chimeric vaccine Sanofi-Pasteur Phase 3 trials with a tetravalent formulation in DENV
endemic countries
2 PDK cell-passaged, live attenuated vaccine WRAIR/GSK Phase 2 trials with a tetravalent formulation in endemic
countries




Phase 1/2 trials with monovalent formulations completed;
tetravalent
phase 1 initiated
4 Dengue prM-E DNA vaccine NMRC Phase 1 with monovalent vaccine completed
5 Recombinant 80 % E subunit antigen vaccine Hawaii Biotech/
Merck
Phase 1 with monovalent vaccine initiated
6 Purified inactivated vaccine WRAIR Phase 1 with monovalent vaccine initiated
7 Live attenuated chimeric DENV vaccine CDC Phase 1 with monovalent vaccine initiated
Abbreviations: PDK, primary dog kidney cells; WRAIR, Walter Reed Army Institute of Research; GSK, GlaxoSmithKline Biologicals; NIH, National Institutes of Health;
prM-E, premembrane-envelope; NMRC, Naval Medical Research Center; CDC, Centers of Disease Control and Prevention
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serotypes in immunized mice after inoculation with live
DENV from each serotype [81].
Dengue prM-E DNA vaccine
A naked DNA-based candidate vaccine against DENV has
been developed by the Naval Medical Research Center
[67, 82, 83]. The genes encoding prM and E of DENV
were cloned into a shuttle vector under the transcriptional
control of human cytomegalovirus (CMV) promoter. The
results of phase I clinical trial showed no adverse effects
except mild injection site pain, swelling, and fatigue. After
second dose, strong IgM and IgG antibody response was
observed which favors the safety profile of this vaccine. To
get a better immunogenicity profile, a vaccine based on
lipid adjuvant Vaxfectin (Vical Incorporated, San Diego,
USA), was developed and the results demonstrated good
protection profile against DENV compared to DNA alone
[84]. Based on this technology, different groups have
developed other candidate vaccines and achieved good
protection in mouse models using envelope glycoproteins
prM and E, the non-structural protein NS1 and the
helicase/protease NS3 as vaccine antigens [85–87].
Purified inactivated vaccine (PIV)
The first purified inactivated vaccine was developed
with aluminum hydroxide (alum) adjuvant and tested
in mice and rhesus macaques in the mid-1990s, by
Walter Reed Army Institute of Research against den-
gue 2 serotype and good virus protection was re-
ported after two doses [88, 89]. Using similar
technology, second generation Japanese encephalitis
(JE) PIV vaccine was developed [90, 91]. Currently, a
new JE vaccine (Ixiaro; Novartis Vaccines) has been
approved for use in many countries, including the
USA [92]. Another dengue vaccine (dengue 1 PIV),
recombinant subunit dengue E glycoprotein antigen
(r80E) was also developed and has entered phase I
clinical trial [93–95]. The Centers for Disease
Control and Prevention (USA) have also developed a
live-attenuated vaccine named DENVax, which was
found to be highly immunogenic in both children
and adults and has currently entered phase I clinical
trial in the United States [96, 97]. Recently, a novel
third generation approach is being used to develop a
vaccine containing recombinant subunit E domain
III (ED3) and the results of laboratory tests have
shown the development of potent neutralizing anti-
bodies in a mouse model [98–100]. Using the same
technology, a tetravalent vaccine was developed and
expressed in Pichia pastoris by splicing and using
flexible pentaglycyl linkers of the four EDIII. The
observed results showed that this antigen elicit spe-
cific antibodies against all four DENV serotypes in
BALB/c mice [101].
Lessons from animal models
Animal models are very useful for vaccine test develop-
ment. The lack of animal models significantly hampered
the development and efficacy testing of dengue vaccine.
Currently only rhesus macaques and Aotus monkeys are
being used for testing the vaccine before clinical trials
are initiated [62]. The D1ME100 vaccine was evaluated
in both Aotus monkeys and rhesus monkeys, and found
to be immunogenic with 80–95 % protection against
dengue infection [102, 103]. Porter et al. (2012) demon-
strated that injection of non-human primate with three
doses on day 1, 28 and 84, with tetravalent dengue DNA
vaccine Vaxfectin-adjuvanted, was more efficient against
live dengue-2 virus compared to control animals. This
finding support initiation of Vaxfectin-adjuvanted phase
I clinical trial [84].
Successful induction of immune response was obtained
in mice and rhesus monkeys to the vaccines developed
using dengue 4 prM-E, dengue 1 prM-E-nonstructural
(NS)1, and dengue 2 NS3 antigens, and PIV adjuvanted
with alum [85, 86]. Centers for Disease Control and
Prevention (Fort Collins, CO), Hawaii biotech, and
Simmons developed different vaccines that showed good
immunogenicity in animal models [104]. Similarly, the
psoralen/UV inactivation dengue vaccine was found to be
more immunogenic and protective against dengue sero-
type 1 virus in Aotus monkeys [105].
Antiviral therapy
Thus far, there are no antiviral drugs available to treat
dengue fever; therefore the community will continue to
depend on the control of the mosquito vector as the
main route to prevent the spread of disease. Alternative
approaches have been utilized against flaviviruses by target-
ing and inhibiting virus entry and the essential elements
used in virus replication, nonstructural proteins, RNA poly-
merase, and proteases. The most important target elements
include NS3 helicase nucleoside triphosphatase (NTPase/
RNA 5’ triphosphatase (RTPase), NS5 methyl transferase/
RNA-dependent RNA polymerase, and NS3/NS2B protease
[106–108].
RNA interference (RNAi) technology is also being
used to impair virus replication against respiratory syn-
cytial virus, hepatitis viruses, influenza virus, poliovirus
and HIV [109, 110]. Low molecular weight phenolic
compounds such as flavonoids and phytochemicals
isolated from plants were previously tested and are being
used for anti-dengue therapy [111, 112]. An anti-viral in-
hibitory effect ranging from 50–75 % against DENV
replication was observed when methanolic extracts of
Momordica charantia and Andrographis paniculata
were used in cultured primate cells [113].
Several attempts have been made in the past to tackle
dengue through elimination of Ae. Aegypti. The most
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successful experiences were related to vector control
programs adopted in Cuba and Singapore. The programs
were based on intensive insecticidal treatment and reduc-
tion of the availability of Aedes larval habitats [18, 114].
Unfortunately, lack of sustainability of these stringent
measures led to reappearance of dengue outbreaks.
Recently, a novel form of biological control of dengue
transmission has been developed and is currently being
applied. This is based on the development of genetically
modified (GM) mosquitoes infected with a bacterium
known as Wolbachia to combat dengue infection. This
bacterium blocks replication of the virus inside the mos-
quito and prevents its transmission to humans [115]. In
2012, 10 million GM male mosquitoes were released in
the wild to decrease the number of Aedes mosquitoes
and reduce the rate of dengue transmission. A closer
monitoring of the insects revealed that over 85 % of the
eggs were Wolbachia-positive which indicated that GM-
mosquitoes were overriding wild-mosquitoes resulting in
decreased virus transmission [116]. In an initiative to
eradicate dengue fever, scientists from Australia, are
leading Eliminate Dengue (ED) program which involves
community engagement as a key component in this
program. Since the program kicked off in 2011, millions
of Wolbachia mosquitoes were released across the North
Queensland city—Australia. Based on the promising re-
sults obtained from local trial, Eliminate Dengue became
an international research program across countries
affected by dengue including Australia, Vietnam,
Indonesia, Brazil and Colombia [117, 118].
Targets of antiviral therapy
Dengue infection can be prevented by alternative
approaches. The first one includes blocking virus entry
into cells which is mediated by the viral envelope
glycoprotein E via receptor-mediated endocytosis
[119]. Dendritic cells, monocytes, and macrophages
are the main targets of DENV infectious entry. The
second approach involves blocking virus attachment to
specific cellular receptors expressed on immune cells,
liver cells, and endothelial cells.
Fusion and glycosidase inhibitors
Small molecules and peptides targeting the hydrophobic
pocket of the envelope E glycoprotein are characterized as
inhibitors of virus entry. Nicholson et al. (2011) explored
the inhibitory effects of DN59 and 1OAN1, peptide entry
inhibitors. The authors demonstrated that DN59 and
1OAN1 can effectively block antibody dependent en-
hancement (ADE) in-vitro suggesting that entry inhibitors
are potential candidates to prevent development of DHF/
DSS [120]. Two other compounds have also been shown
to qualify as potent inhibitors of dengue virus infection
are imino-sugars deoxynojirimycin and castanospermine
[121]. These compounds are natural alkaloids derived
from the black bean and act as inhibitors against all 4
dengue serotypes by disrupting the folding pathways of
the envelope glycoproteins prM and E [122].
Carbohydrate-binding agents
Various types of carbohydrate-binding agents, isolated
from different organisms, have been shown to have anti-
viral activities. Three plant lectins, Hippeastrum hybrid
agglutinin, Galanthus nivalis agglutinin and Urtica dioica
agglutinin isolated from amaryllis, snowdrop and stinging
nettle respectively were found to be potent inhibitors of
DENV-2 infection by inhibiting viral replication [123].
Heparan mimetics
Heparan sulfate (HS) is a putative receptor for DENV
which interacts with domain III of the E-protein. Virus
entry can be blocked by targeting the E-protein-HS
interaction with soluble GAGs and other highly charged
HS [124]. Fucoidan was isolated from marine algae and
showed antiviral activity against DENV-2 in BHK cells
[125]. Similarly, carrageenan and DL galactan, sulfated
polysaccharides from red seaweeds, exhibited strong
antiviral activity against DENV-2 and DENV-3 but a
very weak activity against DENV-4 and DENV-1. Fur-
thermore, two α-D-glucans were isolated from a Chinese
herb and demonstrated high anti-DENV-2 activities in
BHK cells [112, 126].
Conclusions
Dengue fever represents a real economic burden espe-
cially in affected countries. Extensive efforts are needed
to tackle disease spread and reduce the mortality rates
and the associated healthcare cost. There is a need for
more scientific research which we believe is a key route
to provide further insight in the pathogenesis of dengue
infection and help understanding the underlying
molecular mechanisms associated with progression to
the severe forms of the disease (DHF/DSS). This will be
a step forward to develop an adequate preventive
vaccine and effective treatment.
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